NeuroSense Collaborated with NeuraLight to Advance ALS Oculometric Biomarkers Using AI and ML
Shots:
- The companies collaborated to advance digital biomarkers for the detection & monitoring of neurological diseases incl. ALS
- NeuraLight's platform uses computer vision, AI, deep learning algorithms & ML to identify oculometric digital biomarkers to transform clinical development, diagnostics & precision medicine in neurology. The collaboration entails sharing & tracking patient data to advance the use of ALS digital biomarkers in a parallel study
- NeuroSense is conducting a P-IIb (PARADIGM) trial to evaluate the efficacy of NeuroSense's PrimeC for ALS. The effectiveness of NeuraLight's system will be validated by assuring objectivity, reliability & repeatability in trials as well as reducing costs and friction
Ref: PRNewswire | Image: NeuroSense Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
